The manufacturer expects a two-to-four-week delay in deliveries after more than 2,000 workers at its factories were infected by the coronavirus, raising the possibility of supply disruptions during the pandemic.

The one-time antibody treatment, developed by Regeneron Pharmaceuticals, is administered intravenously.

Officials aim to close a loophole that inflated healthcare costs by billions of dollars a year and led to drug shortages.

The move diversifies the Northfield, Ill.-based company’s PPE supply chain, lessening its reliance on Chinese producers.